Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity

Area of Science:

• Immunology
• Cancer Biology
• Gene Therapy

Background:

• Dendritic cells (DCs) are crucial for anti-tumor immunity but are often suppressed within the tumor microenvironment (TME).
• Modulating DC function is a promising strategy to enhance anti-cancer immune responses.
• Fms-like tyrosine kinase receptor 3 ligand (Flt3L) is essential for DC development.

Purpose of the Study:

• To evaluate the efficacy of a novel albumin-fused Flt3L DNA (alb-Flt3L DNA) delivered via electroporation as an anti-cancer immunotherapy.
• To assess the impact of alb-Flt3L DNA on DC expansion, T cell responses, tumor control, and survival.
• To determine the safety profile of the novel immunotherapy.

Main Methods:

• Electroporation-mediated delivery of alb-Flt3L DNA in TC-1-bearing C57BL/6 mice.
• Analysis of DC and cDC1 populations.
• Quantification of IFN-γ-secreting CD8+ T lymphocytes.
• Assessment of tumor growth and animal survival.
• Evaluation of treatment-related toxicity.

Main Results:

• Alb-Flt3L DNA administration via electroporation induced a significant anti-tumor immune response.
• The treatment led to better tumor control and superior survival rates in mice.
• Robust expansion of dendritic cells (DCs) and cDC1s was observed.
• Increased levels of IFN-γ-secreting CD8+ lymphocytes correlated with cDC1 expansion.
• The alb-Flt3L DNA treatment exhibited limited toxicity.

Conclusions:

• Novel electroporation-mediated delivery of alb-Flt3L DNA is a potent strategy for DC-based cancer immunotherapy.
• This approach effectively enhances anti-tumor immunity by promoting DC maturation and cytotoxic T cell responses.
• Alb-Flt3L DNA immunotherapy shows promise for improving cancer treatment outcomes with a favorable safety profile.